50 terminated. 50 Phase 3, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 50 | Terminated 50 |
| Phase 2 | 9 | Terminated 9 |
Follow Neuroectodermal Tumors: new trials by email Literature Review of Neuroectodermal Tumors trials Research Report on Neuroectodermal Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy® JPB898 (Induction and Maintenance), Opdivo-EU (Induction), Opdivo-US (Induction) - Melanoma | Phase 3 | Terminated | Sandoz | 52 | 2024-12-19 | 2026-02-24 |
| A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) Pembrolizumab/Vibostolimab, Pembrolizumab - Melanoma | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 1594 | 2023-01-19 | 2026-09-10 |
| Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas REC-2282, Placebo - Neurofibromatosis Type 2 | Phase 2 / Phase 3 | Terminated | Recursion Pharmaceuticals Inc. | 25 | 2022-06-20 | 2026-08-17 |
| Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION Nivolumab 10 MG/ML - Melanoma (Skin), Melanoma, Stage II | Phase 2 / Phase 3 | Terminated | The Christie NHS Foundation Trust | 8 | 2021-11-08 | 2025-02-27 |
| A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma Nivolumab, Nivolumab + Relatlimab Fixed Dose Combination - Melanoma | Phase 3 | Terminated | Bristol-Myers Squibb | 1093 | 2021-10-19 | 2026-01-08 |
| Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma | Phase 3 | Terminated | NRG Oncology | 19 | 2021-08-05 | 2026-05-20 |
| CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma CMP-001, Nivolumab - Melanoma, Advanced Melanoma | Phase 2 / Phase 3 | Terminated | Regeneron Pharmaceuticals | 20 | 2021-02-24 | 2026-06-15 |
| Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence Bempegaldesleukin, Nivolumab - Melanoma, Melanoma Stage III | Phase 3 | Terminated | Nektar Therapeutics | 765 | 2020-07-27 | 2023-04-21 |
| Pre-Treatment of Highly Suspicious Pigmented Skin Lesions With Interleukin-2 Aldesleukin, Saline - Melanoma (Skin), Melanoma in Situ | Phase 3 | Terminated | Carman Giacomantonio | 1 | 2019-10-30 | 2024-07-24 |
| 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases 131I-omburtamab - Neuroblastoma, CNS Metastases | Phase 2 / Phase 3 | Terminated | Y-mAbs Therapeutics | 52 | 2018-12-11 | 2024-02-13 |
| Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections Brolucizumab, Aflibercept - Age-Related Macular Degeneration | Phase 3 | Terminated | Novartis Pharmaceuticals | 535 | 2018-10-30 | 2023-01-30 |
| A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide Vigil, Irinotecan, Temozolomide - Ewing Sarcoma, Ewing Family of Tumors | Phase 3 | Terminated | Gradalis, Inc. | 32 | 2018-08-21 | 2023-04-26 |
| UNITE Study: Understanding New Interventions With GBM ThErapy Steroid eye drops, Vasoconstrictor eye drops, Cold compress - Glioblastoma Multiforme | Phase 3 | Terminated | AbbVie | 40 | 2018-07-30 | 2021-04-14 |
| A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma Ipilimumab, Tilsotolimod with Ipilimumab - Metastatic Melanoma | Phase 3 | Terminated | Idera Pharmaceuticals, Inc. | 481 | 2018-05-30 | 2022-11-08 |
| Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects Trans Sodium Crocetinate plus SOC, Standard of Care (SOC) - Glioblastoma | Phase 3 | Terminated | Diffusion Pharmaceuticals Inc | 19 | 2018-01-16 | 2021-07-22 |
| VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM VAL-083, Dianhydrogalactitol, Physician's Choice of Salvage Therapy - temozolomide, Physician's Choice of Salvage Therapy - lomustine - Glioblastoma Multiforme, Glioblastoma | Phase 3 | Terminated | DelMar Pharmaceuticals, Inc. | 2 | 2017-10-27 | 2025-09-04 |
| A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma Spartalizumab, Placebo, Dabrafenib - Melanoma | Phase 3 | Terminated | Novartis Pharmaceuticals | 568 | 2017-02-17 | 2025-09-18 |
| The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma Toca 511, Toca FC, Lomustine - Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 2 / Phase 3 | Terminated | Tocagen Inc. | 403 | 2015-11-30 | 2020-02-07 |
| The Effect of Duloxetine on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients duloxetine, PLACEBO - Depression | Phase 3 | Terminated | michal roll | 50 | 2015-05-01 | 2015-12-03 |
| PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma PV-10 (10% rose bengal disodium), Dacarbazine, temozolomide or talimogene laherparepvec - Cutaneous Melanoma | Phase 3 | Terminated | Provectus Biopharmaceuticals, Inc. | 20 | 2015-04-01 | 2022-01-19 |
Showing 20 of 50. Sign in to see all of them.
Melanoma (26) · Glioblastoma (10) · Neoplasm Metastasis (6) · Neoplasms (6) · Astrocytoma (5) · Brain Neoplasms (5) · Neuroblastoma (5) · Breast Neoplasms (3) · Glioma (3) · Lung Neoplasms (3) · Neuroendocrine Tumors (3) · Oligodendroglioma (3) · Recurrence (3) · Sarcoma (3) · Skin Neoplasms (3)
Neoplasms, Germ Cell and Embryonal (50) · Neoplasms, Nerve Tissue (50) · Neoplasms by Histologic Type (49) · Neoplasms (44) · Neoplasms by Site (36) · Neuroendocrine Tumors (31) · Nevi and Melanomas (28) · Skin and Connective Tissue Diseases (28) · Skin Diseases (27) · Skin Neoplasms (23) · Neoplasms, Glandular and Epithelial (21) · Neoplasms, Neuroepithelial (15) · Pathological Conditions, Signs and Symptoms (13) · Pathologic Processes (11)
Temozolomide (8) · Radiotherapy (6) · Nivolumab (4) · Dacarbazine (3) · Bevacizumab (2) · Lomustine (2) · Paclitaxel (2) · pembrolizumab (2) · talimogene laherparepvec (2) · ABT-414 (1) · Atorvastatin (1) · Carboplatin (1) · Carmustine (1) · Cholecalciferol (1) · Cryosurgery (1)
European Organisation for Research and Treatment of Cancer - EORTC (3) · M.D. Anderson Cancer Center (2) · Merck Sharp & Dohme LLC (2) · Novartis Pharmaceuticals (2) · AB Science (1) · AbbVie (1) · Alliance for Clinical Trials in Oncology (1) · American Regent, Inc. (1) · Amgen (1) · Barbara Ann Karmanos Cancer Institute (1) · Bradmer Pharmaceuticals Inc. (1) · Bristol-Myers Squibb (1) · Carman Giacomantonio (1) · Centre Hospitalier Universitaire de Nice (1) · DelMar Pharmaceuticals, Inc. (1)
United States (35) · Italy (16) · United Kingdom (15) · Canada (14) · France (14) · Germany (14) · Spain (13) · Australia (11) · Austria (9) · Netherlands (9) · Poland (9) · Belgium (8) · Czechia (8) · Israel (8) · South Korea (7)
A Colao, M.D. (1) · A Faggiano, M.D. (1) · Alessandro Testori, MD (1) · Ara Vaporciyan, MD, BS (1) · C Gallo, MD (1) · Carman A Giacomantonio, MD, FRCSC (1) · Craig Slingluff, M.D. (1) · David A. Reardon, MD (1) · Donald L. Morton, MD (1)
PMID 22027909, PMID 23401447, PMID 24510314, PMID 24563781, PMID 26189058, PMID 26837440, PMID 27252174, PMID 29896663, PMID 30791889, PMID 33020648, PMID 33119048, PMID 34599031, PMID 35030011, PMID 35073733, PMID 35728875, PMID 37417948, PMID 38464207, PMID 39083105, PMID 39230120, PMID 40048691, PMID 41109920, PMID 41698381, PMID 42585631, PMID 42770835
2004 (2), 2008 (1), 2009 (1), 2014 (1), 2015 (1), 2016 (1), 2017 (1), P01CA012582 (1), P30CA022453 (1), P30CA069533 (1), U10CA081920 (1), U10CA180868 (1)